Therefore, the combined use of CgA (a broad indicator of neuroendocrine cell activity and tumor burden) and SPP1 (associated with aggressive tumor behavior and metastasis) may provide additional benefits for the diagnosis of GEP-NENs. This evidence concerns the gene CGA and neoplasm.